28 results on '"Araiza-Olivera D"'
Search Results
2. In Saccharomyces cerevisiae, withdrawal of the carbon source results in detachment of glycolytic enzymes from the cytoskeleton and in actin reorganization
- Author
-
Espinoza-Simón, E., Chiquete-Félix, N., Morales-García, L., Pedroza-Dávila, U., Pérez-Martínez, X., Araiza-Olivera, D., Torres-Quiroz, F., and Uribe-Carvajal, S.
- Published
- 2020
- Full Text
- View/download PDF
3. Extracting endocrine disrupting compounds from infant formula using supercritical carbon dioxide
- Author
-
Torres-Torres, E.Y., Montiel, Carmina, Araiza-Olivera, D., Gutierrez-Aguilar, M., Gimeno, Miquel, and García-Arrazola, R.
- Published
- 2019
- Full Text
- View/download PDF
4. The association of glycolytic enzymes from Saccharomyces Cerevisiae is stabilized by actin: P12-12
- Author
-
Araiza-Olivera, D., Chiquete-Felix, N., Mújica, A., Uribe-Carvajal, S., and Peña, A.
- Published
- 2012
5. Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors
- Author
-
Araiza-Olivera, D, primary, Feng, Y, additional, Semenova, G, additional, Prudnikova, T Y, additional, Rhodes, J, additional, and Chernoff, J, additional
- Published
- 2017
- Full Text
- View/download PDF
6. Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors
- Author
-
Araiza-Olivera, D, Feng, Y, Semenova, G, Prudnikova, T Y, Rhodes, J, and Chernoff, J
- Abstract
Activating mutations in the RAC1 gene have recently been discovered as driver events in malignant melanoma. Expression of this gene is associated with melanocyte proliferation, and melanoma cells bearing this mutation are insensitive to BRAF inhibitors such as vemurafenib and dabrafenib, and also may evade immune surveillance due to enhanced expression of PD-L1. Activating mutations in RAC1 are of special interest, as small-molecule inhibitors for the RAC effector p21-activated kinase (PAK) are in late-stage clinical development and might impede oncogenic signaling from mutant RAC1. In this work, we explore the effects of PAK inhibition on RAC1P29Ssignaling in zebrafish embryonic development, in the proliferation, survival and motility of RAC1P29S-mutant human melanoma cells, and on tumor formation and progression from such cells in mice. We report that RAC1P29Sevokes a Rasopathy-like phenotype on zebrafish development that can be blocked by inhibitors of PAK or MEK. We also found and that RAC1-mutant human melanoma cells are resistant to clinical inhibitors of BRAF but are uniquely sensitive to PAK inhibitors. These data suggest that suppressing the PAK pathway might be of therapeutic benefit in this type of melanoma.
- Published
- 2018
- Full Text
- View/download PDF
7. Identifying and targeting key driver genes for collagen production within the 11q13/14 breast cancer amplicon.
- Author
-
Araiza-Olivera D, Prudnikova TY, Uribe-Alvarez C, Cai KQ, Franco-Barraza J, Dones JM, Raines RT, and Chernoff J
- Abstract
Breast cancers of the IntClust-2 type, characterized by amplification of a small portion of chromosome 11, have a median survival of only five years. Several cancer-relevant genes occupy this portion of chromosome 11, and it is thought that overexpression of a combination of driver genes in this region is responsible for the poor outcome of women in this group. In this study we used a gene editing method to knock out, one by one, each of 198 genes that are located within the amplified region of chromosome 11 and determined how much each of these genes contributed to the survival of breast cancer cells. In addition to well-known drivers such as CCND1 and PAK1, we identified two different genes (SERPINH1 and P4HA3), that encode proteins involved in collagen synthesis and organization. Using both in vitro and in vivo functional analyses, we determined that P4HA3 and/or SERPINH1 provide a critical driver function on IntClust-2 basic processes, such as viability, proliferation, and migration. Inhibiting these enzymes via genetic or pharmacologic means reduced collagen synthesis and impeded oncogenic signaling transduction in cell culture models, and a small-molecule inhibitor of P4HA3 was effective in treating 11q13 tumor growth in an animal model. As collagen has a well-known association with tissue stiffness and aggressive forms of breast cancer, we believe that the two genes we identified provide an opportunity for a new therapeutic strategy in IntClust-2 breast cancers. Implications: Breast cancers with 11q13/14 chromosomal amplifications may be vulnerable to inhibitors of collagen synthesis.
- Published
- 2025
- Full Text
- View/download PDF
8. Identifying and targeting key driver genes for collagen production within the 11q13/14 breast cancer amplicon.
- Author
-
Araiza-Olivera D, Prudnikova TY, Uribe-Alvarez C, Cai KQ, Franco-Barraza J, Dones JM, Raines RT, and Chernoff J
- Abstract
Genetic studies indicate that breast cancer can be divided into several basic molecular groups. One of these groups, termed IntClust-2, is characterized by amplification of a small portion of chromosome 11 and has a median survival of only five years. Several cancer-relevant genes occupy this portion of chromosome 11, and it is thought that overexpression of a combination of driver genes in this region is responsible for the poor outcome of women in this group. In this study we used a gene editing method to knock out, one by one, each of 198 genes that are located within the amplified region of chromosome 11 and determined how much each of these genes contributed to the survival of breast cancer cells. In addition to well-known drivers such as CCND1 and PAK1 , we identified two different genes ( SERPINH1 and P4HA3 ), that encode proteins involved in collagen synthesis and organization. Using both in vitro and in vivo functional analyses, we determined that P4HA3 and/or SERPINH1 provide a critical driver function on IntClust-2 basic processes, such as viability, proliferation, and migration. Inhibiting these enzymes via genetic or pharmacologic means reduced collagen synthesis and impeded oncogenic signaling transduction in cell culture models, and a small-molecule inhibitor of P4HA3 was effective in treating 11q13 tumor growth in an animal model. As collagen has a well-known association with tissue stiffness and aggressive forms of breast cancer, we believe that the two genes we identified provide an opportunity for a new therapeutic strategy in IntClust-2 breast cancers.
- Published
- 2024
- Full Text
- View/download PDF
9. Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints.
- Author
-
Cannon AC, Budagyan K, Uribe-Alvarez C, Kurimchak AM, Araiza-Olivera D, Cai KQ, Peri S, Zhou Y, Duncan JS, and Chernoff J
- Subjects
- Humans, Proteomics, Melanocytes, Carcinogenesis, Cell Line, Cyclin-Dependent Kinase 9, rac1 GTP-Binding Protein genetics, Melanoma drug therapy, Melanoma genetics
- Abstract
RAC1
P29S is the third most prevalent hotspot mutation in sun-exposed melanoma. RAC1 alterations in cancer are correlated with poor prognosis, resistance to standard chemotherapy, and insensitivity to targeted inhibitors. Although RAC1P29S mutations in melanoma and RAC1 alterations in several other cancers are increasingly evident, the RAC1-driven biological mechanisms contributing to tumorigenesis remain unclear. Lack of rigorous signaling analysis has prevented identification of alternative therapeutic targets for RAC1P29S -harboring melanomas. To investigate the RAC1P29S -driven effect on downstream molecular signaling pathways, we generated an inducible RAC1P29S expression melanocytic cell line and performed RNA-sequencing (RNA-seq) coupled with multiplexed kinase inhibitor beads and mass spectrometry (MIBs/MS) to establish enriched pathways from the genomic to proteomic level. Our proteogenomic analysis identified CDK9 as a potential new and specific target in RAC1P29S -mutant melanoma cells. In vitro, CDK9 inhibition impeded the proliferation of in RAC1P29S -mutant melanoma cells and increased surface expression of PD-L1 and MHC Class I proteins. In vivo, combining CDK9 inhibition with anti-PD-1 immune checkpoint blockade significantly inhibited tumor growth only in melanomas that expressed the RAC1P29S mutation. Collectively, these results establish CDK9 as a novel target in RAC1-driven melanoma that can further sensitize the tumor to anti-PD-1 immunotherapy., (© 2024. The Author(s), under exclusive licence to Springer Nature Limited.)- Published
- 2024
- Full Text
- View/download PDF
10. Unique vulnerability of RAC1 -mutant melanoma to combined inhibition of CDK9 and immune checkpoints.
- Author
-
Cannon AC, Budagyan K, Uribe-Alvarez C, Kurimchak AM, Araiza-Olivera D, Cai KQ, Peri S, Zhou Y, Duncan JS, and Chernoff J
- Abstract
RAC1
P29S is the third most prevalent hotspot mutation in sun-exposed melanoma. RAC1 alterations in cancer are correlated with poor prognosis, resistance to standard chemotherapy, and insensitivity to targeted inhibitors. Although RAC1P29S mutations in melanoma and RAC1 alterations in several other cancers are increasingly evident, the RAC1-driven biological mechanisms contributing to tumorigenesis remain unclear. Lack of rigorous signaling analysis has prevented identification of alternative therapeutic targets for RAC1P29S -harboring melanomas. To investigate the RAC1P29S -driven effect on downstream molecular signaling pathways, we generated an inducible RAC1P29S expression melanocytic cell line and performed RNA-sequencing (RNA-seq) coupled with multiplexed kinase inhibitor beads and mass spectrometry (MIBs/MS) to establish enriched pathways from the genomic to proteomic level. Our proteogenomic analysis identified CDK9 as a potential new and specific target in RAC1P29S -mutant melanoma cells. In vitro , CDK9 inhibition impeded the proliferation of in RAC1P29S -mutant melanoma cells and increased surface expression of PD-L1 and MHC Class I proteins. In vivo , combining CDK9 inhibition with anti-PD-1 immune checkpoint blockade significantly inhibited tumor growth only in melanomas that expressed the RAC1P29S mutation. Collectively, these results establish CDK9 as a novel target in RAC1-driven melanoma that can further sensitize the tumor to anti-PD-1 immunotherapy., Competing Interests: Authors’ Disclosures The authors declare no competing financial interests.- Published
- 2023
- Full Text
- View/download PDF
11. The cytotoxicity effect of 7-hydroxy-3,4-dihydrocadalene from Heterotheca inuloides and semisynthetic cadalenes derivates towards breast cancer cells: involvement of oxidative stress-mediated apoptosis.
- Author
-
Mendoza-Fuentes A, González-Burgos E, Aparicio Trejo OE, Delgado-Lamas G, Rodríguez-Chávez JL, Pedraza-Chaverri J, Gómez-Serranillos MP, and Araiza-Olivera D
- Subjects
- Humans, Female, Caspase 3 metabolism, Reactive Oxygen Species metabolism, Oxidative Stress, Apoptosis, Proto-Oncogene Proteins c-bcl-2 metabolism, Asteraceae chemistry, Breast Neoplasms drug therapy, Antineoplastic Agents pharmacology
- Abstract
Background: Heterotheca inuloides , traditionally employed in Mexico, has demonstrated anticancer activities. Although it has been proven that the cytotoxic effect is attributed to cadinane-type sesquiterpenes such as 7-hydroxy-3,4-dihydrocadalene, the mechanism of action by which these agents act in tumor lines and their regulation remain unknown. This study was undertaken to investigate for first time the cytotoxic activity and mechanism of action of 7-hydroxy-3,4-dihydrocadalene and two semi-synthetic cadinanes derivatives towards breast cancer cells., Methods: Cell viability and proliferation were assayed by thiazolyl blue tetrazolium bromide (MTT) assay and Trypan blue dye exclusion assay. Cell migration measure was tested by wound-healing assay. Moreover, the reactive oxygen species (ROS) and lipid peroxidation generation were measured by 2',7'-dichlorofluorescein diacetate (DCFH-DA) assay and thiobarbituric acid reactive substance (TBARS) assay, respectively. Furthermore, expression of caspase-3, Bcl-2 and GAPDH were analyzed by western blot., Results: The results showed that 7-hydroxy-3,4-dihydrocadalene inhibited MCF7 cell viability in a concentration and time dependent manner. The cytotoxic potency of semisynthetic derivatives 7-(phenylcarbamate)-3,4-dihydrocadalene and 7-(phenylcarbamate)-cadalene was remarkably lower. Moreover, in silico studies showed that 7-hydroxy-3,4-dihydrocadalene, and not so the semi-synthetic derivatives, has optimal physical-chemical properties to lead a promising cytotoxic agent. Further examination on the action mechanism of 7-hydroxy-3,4-dihydrocadalene suggested that this natural product exerted cytotoxicity via oxidative stress as evidenced in a significantly increase of intracellular ROS levels and in an induction of lipid peroxidation. Furthermore, the compound increased caspase-3 and caspase-9 activities and slightly inhibited Bcl-2 levels. Interestingly, it also reduced mitochondrial ATP synthesis and induced mitochondrial uncoupling., Conclusion: Taken together, 7-hydroxy-3,4-dihydrocadalene is a promising cytotoxic compound against breast cancer via oxidative stress-induction., Competing Interests: Elena Gonzalez-Burgos is an Academic Editor for PeerJ. Daniela Araiza-Olivera is employed by Fox Chase Cancer Center., (© 2023 Mendoza-Fuentes et al.)
- Published
- 2023
- Full Text
- View/download PDF
12. The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells.
- Author
-
Kurimchak AM, Herrera-Montávez C, Montserrat-Sangrà S, Araiza-Olivera D, Hu J, Neumann-Domer R, Kuruvilla M, Bellacosa A, Testa JR, Jin J, and Duncan JS
- Subjects
- Animals, Humans, Mice, Drug Resistance, Lapatinib, Protein Kinase Inhibitors, Proteolysis, Proteomics, Proto-Oncogene Proteins p21(ras), Colorectal Neoplasms drug therapy, Colorectal Neoplasms genetics
- Abstract
Proteolysis-targeting chimeras (PROTACs) are a promising new class of drugs that selectively degrade cellular proteins of interest. PROTACs that target oncogene products are avidly being explored for cancer therapies, and several are currently in clinical trials. Drug resistance is a substantial challenge in clinical oncology, and resistance to PROTACs has been reported in several cancer cell models. Here, using proteomic analysis, we found intrinsic and acquired resistance mechanisms to PROTACs in cancer cell lines mediated by greater abundance or production of the drug efflux pump MDR1. PROTAC-resistant cells were resensitized to PROTACs by genetic ablation of ABCB1 (which encodes MDR1) or by coadministration of MDR1 inhibitors. In MDR1-overexpressing colorectal cancer cells, degraders targeting either the kinases MEK1/2 or the oncogenic mutant GTPase KRAS
G12C synergized with the dual epidermal growth factor receptor (EGFR/ErbB)/MDR1 inhibitor lapatinib. Moreover, compared with single-agent therapies, combining MEK1/2 degraders with lapatinib improved growth inhibition of MDR1-overexpressing KRAS-mutant colorectal cancer xenografts in mice. Together, our findings suggest that concurrent blockade of MDR1 will likely be required with PROTACs to achieve durable protein degradation and therapeutic response in cancer.- Published
- 2022
- Full Text
- View/download PDF
13. Diastereomeric Separation of Chiral fac -Tricarbonyl(iminopyridine) Rhenium(I) Complexes and Their Cytotoxicity Studies: Approach toward an Action Mechanism against Glioblastoma.
- Author
-
Suárez-Ortiz GA, Hernández-Correa R, Morales-Moreno MD, Toscano RA, Ramirez-Apan MT, Hernandez-Garcia A, Amézquita-Valencia M, and Araiza-Olivera D
- Subjects
- Crystallography, X-Ray, Humans, Ligands, Models, Molecular, Molecular Structure, Glioblastoma drug therapy, Rhenium chemistry
- Abstract
A series of new (tricarbonyl)rhenium(I) complexes were synthesized using chiral bidentate ligands (+)/(-)-iminopyridines (L
R /LS ). The reaction yielded a mixture of mononuclear Re(I) diastereoisomers, formulated as fac -[Br(CO)3 Re( S / R ) L( S / R ) ]. Each single diastereoisomer was isolated and fully characterized. X-ray crystallography and circular dichroism spectra verified their enantiomeric nature. The cytotoxicity of each complex was evaluated against six cancer cell lines. The effect of the two complexes on viability, proliferation, and migration was analyzed on glioblastoma cell lines (U251 and LN229). Changes in the expression of histones, apoptotic, and key signaling proteins, as well as alterations in DNA structure, were also observed. These experiments showed that the chirality associated with both metal and ligand has a strong influence on cytotoxicity.- Published
- 2022
- Full Text
- View/download PDF
14. PAK1 inhibition reduces tumor size and extends the lifespan of mice in a genetically engineered mouse model of Neurofibromatosis Type 2 (NF2).
- Author
-
Hawley E, Gehlhausen J, Karchugina S, Chow HY, Araiza-Olivera D, Radu M, Smith A, Burks C, Jiang L, Li X, Bessler W, Masters A, Edwards D, Burgin C, Jones D, Yates C, Clapp DW, Chernoff J, and Park SJ
- Subjects
- Animals, Cell Proliferation drug effects, Cell Survival drug effects, Disease Models, Animal, Genes, Tumor Suppressor drug effects, Indoles, Longevity, Mice, Neurilemmoma genetics, Neurofibromatosis 2 metabolism, Neurofibromin 2 genetics, Phosphorylation, Piperidines, Pyrimidines, Schwann Cells metabolism, p21-Activated Kinases genetics, Neurofibromatosis 2 genetics, p21-Activated Kinases metabolism
- Abstract
Neurofibromatosis Type II (NF2) is an autosomal dominant cancer predisposition syndrome in which germline haploinsufficiency at the NF2 gene confers a greatly increased propensity for tumor development arising from tissues of neural crest derived origin. NF2 encodes the tumor suppressor, Merlin, and its biochemical function is incompletely understood. One well-established function of Merlin is as a negative regulator of group A serine/threonine p21-activated kinases (PAKs). In these studies we explore the role of PAK1 and its closely related paralog, PAK2, both pharmacologically and genetically, in Merlin-deficient Schwann cells and in a genetically engineered mouse model (GEMM) that develops spontaneous vestibular and spinal schwannomas. We demonstrate that PAK1 and PAK2 are both hyper activated in Merlin-deficient murine schwannomas. In preclinical trials, a pan Group A PAK inhibitor, FRAX-1036, transiently reduced PAK1 and PAK2 phosphorylation in vitro, but had insignificant efficacy in vivo. NVS-PAK1-1, a PAK1 selective inhibitor, had a greater but still minimal effect on our GEMM phenotype. However, genetic ablation of Pak1 but not Pak2 reduced tumor formation in our NF2 GEMM. Moreover, germline genetic deletion of Pak1 was well tolerated, while conditional deletion of Pak2 in Schwann cells resulted in significant morbidity and mortality. These data support the further development of PAK1-specific small molecule inhibitors and the therapeutic targeting of PAK1 in vestibular schwannomas and argue against PAK1 and PAK2 existing as functionally redundant protein isoforms in Schwann cells., (© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
15. Targeting effector pathways in RAC1 P29S -driven malignant melanoma.
- Author
-
Uribe-Alvarez C, Guerrero-Rodríguez SL, Rhodes J, Cannon A, Chernoff J, and Araiza-Olivera D
- Subjects
- Animals, Apoptosis, Cell Proliferation, Embryo, Nonmammalian metabolism, Embryo, Nonmammalian pathology, Humans, Melanoma genetics, Melanoma metabolism, Melanoma pathology, Phosphatidylinositol 3-Kinases chemistry, Serum Response Factor antagonists & inhibitors, Signal Transduction, Trans-Activators antagonists & inhibitors, Tumor Cells, Cultured, Zebrafish, p21-Activated Kinases antagonists & inhibitors, Embryo, Nonmammalian drug effects, Enzyme Inhibitors pharmacology, Gene Expression Regulation, Neoplastic drug effects, Melanoma drug therapy, Mutation, rac1 GTP-Binding Protein genetics
- Abstract
Malignant melanoma is characterized by mutations in a number of driver genes, most notably BRAF and NRAS . Recent genomic analyses revealed that 4-9% of sun-exposed melanomas bear activating mutations in RAC1 , which encodes a small GTPase that is known to play key roles in cell proliferation, survival, and migration. The RAC1 protein activates several effector pathways, including Group A p21-activated kinases (PAKs), phosphoinositol-3-kinases (PI3Ks), in particular the beta isoform, and the serum-response factor/myocardin-related transcription factor (SRF/MRTF). Having previously shown that inhibition of Group A PAKs impedes oncogenic signalling from RAC1
P29S , we here extend this analysis to examine the roles of PI3Ks and SRF/MRTF in melanocytes and/or in a zebrafish model. We demonstrate that a selective Group A PAK inhibitor (Frax-1036), a pan-PI3K (BKM120), and two PI3Kβ inhibitors (TGX221, GSK2636771) impede the growth of melanoma cells driven by mutant RAC1 but not by mutant BRAF, while other PI3K selective inhibitors, including PI3Kα, δ and γ, are less effective. Using these compounds as well as an SRF/MRTF inhibitor (CCG-203,971), we observed similar results in vivo , using embryonic zebrafish development as a readout. These results suggest that targeting Group A PAKs, PI3Kβ, and/or SRF/MRTF represent a promising approach to suppress RAC1 signalling in malignant melanoma.- Published
- 2021
- Full Text
- View/download PDF
16. Synthesis, structure, and biological activity of bis(benzimidazole)amino thio- and selenoether nickel complexes.
- Author
-
Muñoz-Patiño N, Sánchez-Eguía BN, Araiza-Olivera D, Flores-Alamo M, Hernández-Ortega S, Martínez-Otero D, and Castillo I
- Subjects
- Antineoplastic Agents chemistry, Cell Survival drug effects, Crystallography, X-Ray methods, Humans, Ligands, Molecular Structure, Neoplasms drug therapy, Neoplasms pathology, Tumor Cells, Cultured, Antineoplastic Agents pharmacology, Benzimidazoles chemistry, Coordination Complexes chemistry, Coordination Complexes pharmacology, Copper chemistry, Nickel chemistry
- Abstract
Four new nickel (II) complexes with bis(benzimidazole)thio- and selenoether-based ligands have been synthesized and characterized in the solid state by elemental analysis, IR, magnetic susceptibility and X-ray crystallography, and in solution by FAB
+ mass spectrometry, UV-vis spectroscopy and cyclic voltammetry. Single-crystal X-ray diffraction analysis of the compounds revealed octahedral geometries for all nickel centers. Three of the four complexes are dimers with chloride bridges between the two Ni(II) ions. However, in solution all complexes have a monomeric formulation, based on mass spectrometry and osmometry measurements. The complexes were also screened for their cytotoxic activity on human cell lines (HeLa, SK-LU-1 and HEK-293), and compared with a related Cu(II) complex., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2020 Elsevier Inc. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
17. Fluorescent Probe for Transmembrane Dynamics during Osmotic Effects.
- Author
-
Palacios-Serrato E, Araiza-Olivera D, and Jiménez-Sánchez A
- Subjects
- Cell Line, Tumor, Humans, Osmotic Pressure physiology, Fluorescent Dyes chemistry, Microscopy, Confocal, Mitochondria chemistry, Mitochondrial Dynamics physiology
- Abstract
Membrane tension pores determine organelle dynamics and functions, giving rise to physical observables during the cell death process. While fluorescent organelle-targeted probes for specific chemical analytes are increasingly available, subcellular dynamic processes involving not only chemical parameters but also physicochemical and physical parameters are uncommon. Here, we report a mitochondrial chemical probe, named RCN , rationally designed to monitor osmotic effects during transmembrane tension pore formation by using local mitochondrial polarity and a subcellular localization redistribution property of the probe. Utilizing fluorescence spectroscopy, high-resolution confocal imaging, and spectrally resolved confocal microscopy, we provide a new correlation between mitochondrial dynamics and bleb vesicle formation using osmotic pressure stimuli in the cell, where the mitochondrial local polarity was found to drastically increase. The RCN provides a reliable protocol to assess transmembrane pore formation driven by osmotic pressure increments through local polarity variations and is a more robust physicochemical parameter allowing the health and decease status of the cell to be measured.
- Published
- 2020
- Full Text
- View/download PDF
18. A simple method for mitochondrial respiration and calcium uptake assessment in pollen tubes.
- Author
-
Ortiz-Jiménez DJ, López-Aquino CM, Flores-Herrera C, Preciado-Linares G, Gonzalez-Vizueth I, García-Arrazola R, Araiza-Olivera D, and Gutiérrez-Aguilar M
- Abstract
Key mitochondrial processes are known to be widely conserved throughout the eukaryotic domain. However, the scarce availability of working materials may restrict the assessment of such mitochondrial activities in several working models. Pollen tube mitochondrial studies represent one example of this, where tests have been often restricted due the physical impossibility of performing experiments with isolated mitochondria in enough quantities. Here we detail a method to measure in situ mitochondrial respiratory chain activity and calcium transport in tobacco pollen tubes. • Digitonin-mediated plasmalemma permeabilization allows efficient assessment of mitochondrial respiration and calcium uptake. • This method allows quick, reliable and portable measurements from low to high cellular densities, versus methods requiring intracellular calcium reporters.
- Published
- 2019
- Full Text
- View/download PDF
19. Organotin(iv) differential fluorescent probe for controlled subcellular localization and nuclear microviscosity monitoring.
- Author
-
Bernal-Escalante J, López-Vázquez A, Araiza-Olivera D, and Jiménez-Sánchez A
- Abstract
A dual-emissive fluorescent probe enabling dynamic changes in nuclear local microviscosity monitoring was developed. The new sensing scenario involves probe subcellular localization redistribution, allowing a quantitative analysis of the local microviscosity related to nuclear damage in the presence of agents perturbing the nuclear morphology. With the aid of an organotin(iv) in situ formed complex we propose a different scenario of bioanalytical applications through confocal microscopy.
- Published
- 2019
- Full Text
- View/download PDF
20. Exposure to bisphenol A: current levels from food intake are toxic to human cells.
- Author
-
Hernández-Hernández KL, Tapia-Orozco N, Gimeno M, Espinosa-García AM, García-García JA, Araiza-Olivera D, Sánchez-Bartez F, Gracia-Mora I, Gutierrez-Aguilar M, and García-Arrazola R
- Subjects
- 3T3-L1 Cells drug effects, Animals, Food Contamination, Humans, Inhibitory Concentration 50, MCF-7 Cells drug effects, Mice, PC-3 Cells drug effects, Benzhydryl Compounds adverse effects, Benzhydryl Compounds toxicity, Cell Line drug effects, Phenols adverse effects, Phenols toxicity
- Abstract
In the present work, cell lines of different origin were exposed to BPA levels from food intake reported elsewhere. Specifically, we used an in vitro assay to determine cytotoxicity of BPA in three cell lines: MCF7 (breast cancer), PC3 (prostate cancer) and 3T3-L1 (mouse fibroblast). Cytotoxic effects were observed at concentrations higher than 50 μg/mL which is above the involuntary exposure level of BPA described before in fresh, canned and frozen foods and beverages. Furthermore, medial inhibitory concentrations (IC50) of 85.17 μg/mL and 88.48 μg/mL were observed for PC3 and 3T3-L1, respectively, and a slightly lower IC50 of 64.67 μg/mL for MCF7. These results highlight BPA's toxicity potential at current levels from food intake. The cell line-dependent divergent response to BPA reported herein is discussed.
- Published
- 2019
- Full Text
- View/download PDF
21. Bichromophoric Sensors for Ratiometric Measurements of Molecular Microenvironments through the Interplay of Charge Transfer and Energy Transfer Channels.
- Author
-
Arroyo-Pieck A, Araiza-Olivera D, and Peon J
- Abstract
A new molecular architecture was designed to amplify the sensitivity of bichromophoric probes, in which two sequential kinetic competitions of photophysical channels were used to define the emission yield of the lower energy chromophore. Additionally, the emission from both chromophores can be used for ratiometric measurements, which are concentration independent. Two sensors were synthesized to demonstrate the concept, coupling a boron-dipyrromethene (BODIPY) dye and a cyanine dye. Both the energy transfer from the BODIPY to the cyanine and the cyanine radiative channel compete with a charge transfer state formation, giving the cyanine emission intensity a twofold dependence on polarity. This was confirmed with steady state and time-resolved spectroscopies. Also, the large spectral gap between the two emissions (approx. 280 nm) makes the ratiometric measurements crosstalk-free. The use of the sensors in live cells was demonstrated through the staining and imaging of SK-LU-1 lung cells under normal and apoptotic conditions., (© 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.)
- Published
- 2018
- Full Text
- View/download PDF
22. Hras helps hippo heterodimerize to evade tumor suppression.
- Author
-
Araiza-Olivera D and Chernoff J
- Subjects
- Amino Acid Sequence, Animals, Humans, Neoplasms pathology, Neoplasms metabolism, Protein Multimerization, Protein Serine-Threonine Kinases chemistry, Protein Serine-Threonine Kinases metabolism, Proto-Oncogene Proteins p21(ras) metabolism
- Abstract
Ras oncoproteins can promote or suppress cellular apoptosis, but the mechanisms underlying these varied responses remain incompletely understood. Ras is linked to the Hippo tumor suppressor pathway, a highly conserved signaling cassette that regulates organ size in animals ranging from flies to humans. The proximal members of this pathway, Mammalian Ste20-like kinases (Msts) -1 and -2, self-associate in homodimers and also form heterodimers with other proteins. Formation of such complexes is known to regulate Mst kinase activity and thus, the Hippo pathway. In a manuscript that recently appeared in Current Biology, we showed that activated Hras promotes the formation of Mst1/Mst2 heterodimers, that activation of Erk was required for this event, and that these heterodimers were much less active than Mst1/Mst1 or Mst2/Mst2 homodimers. Interestingly, the formation of such heterodimers was required to deactivate the Hippo pathway and to enable transformation by Hras. In this Commentary, we discuss the background for this study and surprising implications thereof.
- Published
- 2018
- Full Text
- View/download PDF
23. Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition.
- Author
-
Villamar Cruz O, Prudnikova TY, Araiza-Olivera D, Perez-Plasencia C, Johnson N, Bernhardy AJ, Slifker M, Renner C, Chernoff J, and Arias-Romero LE
- Subjects
- Animals, Apoptosis drug effects, Cell Line, Tumor, Cell Survival drug effects, Cell Survival genetics, Chromosomes, Human, Pair 11 genetics, DNA Damage drug effects, Disease Models, Animal, Drug Synergism, Fanconi Anemia Complementation Group Proteins deficiency, Female, Gene Amplification, Gene Expression Regulation, Neoplastic drug effects, Homologous Recombination, Humans, Mice, Xenograft Model Antitumor Assays, p21-Activated Kinases genetics, Antineoplastic Agents pharmacology, Breast Neoplasms genetics, Breast Neoplasms metabolism, Drug Resistance, Neoplasm genetics, Fanconi Anemia Complementation Group Proteins genetics, Poly(ADP-ribose) Polymerase Inhibitors pharmacology, p21-Activated Kinases metabolism
- Abstract
Cells that are deficient in homologous recombination, such as those that have mutations in any of the Fanconi Anemia (FA)/BRCA genes, are hypersensitive to inhibition of poly(ADP-ribose) polymerase (PARP). However, FA/BRCA-deficient tumors represent a small fraction of breast cancers, which might restrict the therapeutic utility of PARP inhibitor monotherapy. The gene encoding the serine-threonine protein kinase p21-activated kinase 1 (PAK1) is amplified and/or overexpressed in several human cancer types including 25-30% of breast tumors. This enzyme controls many cellular processes by phosphorylating both cytoplasmic and nuclear substrates. Here, we show that depletion or pharmacological inhibition of PAK1 down-regulated the expression of genes involved in the FA/BRCA pathway and compromised the ability of cells to repair DNA by Homologous Recombination (HR), promoting apoptosis and reducing colony formation. Combined inhibition of PAK1 and PARP in PAK1 overexpressing breast cancer cells had a synergistic effect, enhancing apoptosis, suppressing colony formation, and delaying tumor growth in a xenograft setting. Because reduced PAK1 activity impaired FA/BRCA function, inhibition of this kinase in PAK1 amplified and/or overexpressing breast cancer cells represents a plausible strategy for expanding the utility of PARP inhibitors to FA/BRCA-proficient cancers.
- Published
- 2016
- Full Text
- View/download PDF
24. H-ras Inhibits the Hippo Pathway by Promoting Mst1/Mst2 Heterodimerization.
- Author
-
Rawat SJ, Araiza-Olivera D, Arias-Romero LE, Villamar-Cruz O, Prudnikova TY, Roder H, and Chernoff J
- Subjects
- HEK293 Cells, Hippo Signaling Pathway, Humans, Intracellular Signaling Peptides and Proteins, MAP Kinase Signaling System, Serine-Threonine Kinase 3, Genes, ras, Protein Multimerization, Protein Serine-Threonine Kinases metabolism
- Abstract
The protein kinases Mst1 and Mst2 have tumor suppressor activity, but their mode of regulation is not well established. Mst1 and Mst2 are broadly expressed and may have certain overlapping functions in mammals, as deletions of both Mst1 and Mst2 together are required for tumorigenesis in mouse models [1-3]. These kinases act via a three-component signaling cascade comprising Mst1 and Mst2, the protein kinases Lats1 and Lats2, and the transcriptional coactivators Yap and Taz [4-6]. Mst1 and Mst2 contain C-terminal SARAH domains that mediate their homodimerization as well as heterodimerization with other SARAH domain-containing proteins, which may regulate Mst1/Mst2 activity. Here we show that, in addition to forming homodimers, Mst1 and Mst2 heterodimerize in cells, this interaction is mediated by their SARAH domains and is favored over homodimers, and these heterodimers have much-reduced protein kinase activity compared to Mst1 or Mst2 homodimers. Mst1/Mst2 heterodimerization is strongly promoted by oncogenic H-ras, and this effect requires activation of the Erk pathway. Cells lacking Mst1, in which Mst1/Mst2 heterodimers are not possible, are resistant to H-ras-mediated transformation and maintain active hippo pathway signaling compared to wild-type cells or cells lacking both Mst1 and Mst2. Our results suggest that H-ras, via an Erk-dependent mechanism, downregulates Mst1/Mst2 activity by inducing the formation of inactive Mst1/Mst2 heterodimers., (Copyright © 2016 Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
25. A glycolytic metabolon in Saccharomyces cerevisiae is stabilized by F-actin.
- Author
-
Araiza-Olivera D, Chiquete-Felix N, Rosas-Lemus M, Sampedro JG, Peña A, Mujica A, and Uribe-Carvajal S
- Subjects
- Actin Cytoskeleton drug effects, Actins agonists, Actins antagonists & inhibitors, Actins chemistry, Antibodies, Fungal pharmacology, Bridged Bicyclo Compounds, Heterocyclic pharmacology, Cytochalasin D pharmacology, Cytoplasm drug effects, Cytoplasm enzymology, Cytoplasm metabolism, Enzyme Stability drug effects, Fermentation drug effects, Kinetics, Multienzyme Complexes antagonists & inhibitors, Multienzyme Complexes chemistry, Phalloidine pharmacology, Polymerization drug effects, Saccharomyces cerevisiae drug effects, Saccharomyces cerevisiae enzymology, Saccharomyces cerevisiae Proteins agonists, Saccharomyces cerevisiae Proteins antagonists & inhibitors, Saccharomyces cerevisiae Proteins chemistry, Thiazolidines pharmacology, Trehalose pharmacology, Tubulin Modulators pharmacology, Viscosity, Actin Cytoskeleton metabolism, Actins metabolism, Glycolysis drug effects, Metabolome drug effects, Multienzyme Complexes metabolism, Saccharomyces cerevisiae metabolism, Saccharomyces cerevisiae Proteins metabolism
- Abstract
In the Saccharomyces cerevisiae glycolytic pathway, 11 enzymes catalyze the stepwise conversion of glucose to two molecules of ethanol plus two CO₂ molecules. In the highly crowded cytoplasm, this pathway would be very inefficient if it were dependent on substrate/enzyme diffusion. Therefore, the existence of a multi-enzymatic glycolytic complex has been suggested. This complex probably uses the cytoskeleton to stabilize the interaction of the various enzymes. Here, the role of filamentous actin (F-actin) in stabilization of a putative glycolytic metabolon is reported. Experiments were performed in isolated enzyme/actin mixtures, cytoplasmic extracts and permeabilized yeast cells. Polymerization of actin was promoted using phalloidin or inhibited using cytochalasin D or latrunculin. The polymeric filamentous F-actin, but not the monomeric globular G-actin, stabilized both the interaction of isolated glycolytic pathway enzyme mixtures and the whole fermentation pathway, leading to higher fermentation activity. The associated complexes were resistant against inhibition as a result of viscosity (promoted by the disaccharide trehalose) or inactivation (using specific enzyme antibodies). In S. cerevisiae, a glycolytic metabolon appear to assemble in association with F-actin. In this complex, fermentation activity is enhanced and enzymes are partially protected against inhibition by trehalose or by antibodies., (© 2013 FEBS.)
- Published
- 2013
- Full Text
- View/download PDF
26. A critical tyrosine residue determines the uncoupling protein-like activity of the yeast mitochondrial oxaloacetate carrier.
- Author
-
Luévano-Martínez LA, Barba-Ostria C, Araiza-Olivera D, Chiquete-Félix N, Guerrero-Castillo S, Rial E, Georgellis D, and Uribe-Carvajal S
- Subjects
- Amino Acid Motifs, Anion Transport Proteins chemistry, Anion Transport Proteins genetics, Hydrogen-Ion Concentration, Linoleic Acid pharmacology, Linoleic Acid physiology, Membrane Potential, Mitochondrial, Mitochondria metabolism, Mitochondrial Proteins chemistry, Mitochondrial Proteins genetics, Oxaloacetic Acid metabolism, Phylogeny, Point Mutation, Protons, Saccharomyces cerevisiae genetics, Saccharomyces cerevisiae Proteins chemistry, Saccharomyces cerevisiae Proteins genetics, Sequence Alignment, Sulfates metabolism, Anion Transport Proteins metabolism, Mitochondrial Proteins metabolism, Saccharomyces cerevisiae Proteins metabolism, Yarrowia genetics
- Abstract
The mitochondrial Oac (oxaloacetate carrier) found in some fungi and plants catalyses the uptake of oxaloacetate, malonate and sulfate. Despite their sequence similarity, transport specificity varies considerably between Oacs. Indeed, whereas ScOac (Saccharomyces cerevisiae Oac) is a specific anion-proton symporter, the YlOac (Yarrowia lipolytica Oac) has the added ability to transport protons, behaving as a UCP (uncoupling protein). Significantly, we identified two amino acid changes at the matrix gate of YlOac and ScOac, tyrosine to phenylalanine and methionine to leucine. We studied the role of these amino acids by expressing both wild-type and specifically mutated Oacs in an Oac-null S. cerevisiae strain. No phenotype could be associated with the methionine to leucine substitution, whereas UCP-like activity was dependent on the presence of the tyrosine residue normally expressed in the YlOac, i.e. Tyr-ScOac mediated proton transport, whereas Phe-YlOac lost its protonophoric activity. These findings indicate that the UCP-like activity of YlOac is determined by the tyrosine residue at position 146.
- Published
- 2012
- Full Text
- View/download PDF
27. Physiological uncoupling of mitochondrial oxidative phosphorylation. Studies in different yeast species.
- Author
-
Guerrero-Castillo S, Araiza-Olivera D, Cabrera-Orefice A, Espinasa-Jaramillo J, Gutiérrez-Aguilar M, Luévano-Martínez LA, Zepeda-Bastida A, and Uribe-Carvajal S
- Subjects
- Debaryomyces metabolism, Ion Channels genetics, Mitochondrial Proteins genetics, Oxidative Phosphorylation, Oxidoreductases metabolism, Reactive Oxygen Species metabolism, Saccharomyces cerevisiae metabolism, Uncoupling Protein 1, Yarrowia metabolism, Ion Channels metabolism, Mitochondrial Proteins metabolism, Saccharomycetales metabolism
- Abstract
Under non-phosphorylating conditions a high proton transmembrane gradient inhibits the rate of oxygen consumption mediated by the mitochondrial respiratory chain (state IV). Slow electron transit leads to production of reactive oxygen species (ROS) capable of participating in deleterious side reactions. In order to avoid overproducing ROS, mitochondria maintain a high rate of O(2) consumption by activating different exquisitely controlled uncoupling pathways. Different yeast species possess one or more uncoupling systems that work through one of two possible mechanisms: i) Proton sinks and ii) Non-pumping redox enzymes. Proton sinks are exemplified by mitochondrial unspecific channels (MUC) and by uncoupling proteins (UCP). Saccharomyces. cerevisiae and Debaryomyces hansenii express highly regulated MUCs. Also, a UCP was described in Yarrowia lipolytica which promotes uncoupled O(2) consumption. Non-pumping alternative oxido-reductases may substitute for a pump, as in S. cerevisiae or may coexist with a complete set of pumps as in the branched respiratory chains from Y. lipolytica or D. hansenii. In addition, pumps may suffer intrinsic uncoupling (slipping). Promising models for study are unicellular parasites which can turn off their aerobic metabolism completely. The variety of energy dissipating systems in eukaryote species is probably designed to control ROS production in the different environments where each species lives.
- Published
- 2011
- Full Text
- View/download PDF
28. The association of glycolytic enzymes from yeast confers resistance against inhibition by trehalose.
- Author
-
Araiza-Olivera D, Sampedro JG, Mújica A, Peña A, and Uribe-Carvajal S
- Subjects
- Enzyme Inhibitors, Fructose-Bisphosphate Aldolase antagonists & inhibitors, Glucosephosphate Dehydrogenase antagonists & inhibitors, Glucosephosphate Dehydrogenase metabolism, Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating) antagonists & inhibitors, Glycolysis, Hexokinase antagonists & inhibitors, L-Lactate Dehydrogenase antagonists & inhibitors, L-Lactate Dehydrogenase metabolism, Phosphoglycerate Kinase antagonists & inhibitors, Saccharomyces cerevisiae growth & development, Saccharomyces cerevisiae Proteins antagonists & inhibitors, Trehalose pharmacology, Fructose-Bisphosphate Aldolase metabolism, Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating) metabolism, Hexokinase metabolism, Phosphoglycerate Kinase metabolism, Saccharomyces cerevisiae metabolism, Saccharomyces cerevisiae Proteins metabolism, Trehalose metabolism
- Abstract
During stress, many organisms accumulate compatible solutes. These solutes must be eliminated upon return to optimal conditions as they inhibit cell metabolism and growth. In contrast, enzyme interactions optimize metabolism through mechanisms such as channeling of substrates. It was decided to test the (compatible solute) trehalose-mediated inhibition of some yeast glycolytic pathway enzymes known to associate and whether inhibition is prevented when enzymes are allowed to associate. Trehalose inhibited the isolated glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and hexokinase (HXK), but not aldolase (ALD) nor phosphoglycerate kinase (PGK). When these enzymes were mixed in pairs, both GAPDH and HXK were protected by either ALD or PGK acquiring the inhibition behavior of the resistant enzyme. GAPDH was not protected by HXK, albumin or lactate dehydrogenase (LDH). Also, ALD did not protect glucose 6-phosphate dehydrogenase (G6PDH), suggesting that protection is specific. In yeast cell extracts, fermentation was resistant to trehalose inhibition, suggesting all enzymes involved in the glucose-dependent production of ethanol were stabilized. It is suggested that during the yeast stress response, enzyme association protects some metabolic pathways against trehalose-mediated inhibition.
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.